MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels, according to UBS.
Get this delivered to your inbox, and more info about our products and services.
Barclays' $1,350 price target implies upside of 32%.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
The investment bank upgraded the pharma stock to overweight from equal weight.
The investment bank upgraded the pharmaceutical name to buy from neutral.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing…
